Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.